ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a ...

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

As more research is done on biological products, including cutting-edge cell ... research and development. This would help advance “proactive research and development in drug discovery ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Induced pluripotent stem cells (iPSCs) have emerged as a transformative force in the realms of regenerative medicine, disease modeling, and drug discovery ... iPSCs is revolutionizing drug development ...

A "pocket" on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct ...

A collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging ...

The University of Chicago and health care investment firm Deerfield Management announced on Jan. 28 the launch of Hyde Park Discovery, a collaboration aiming to advance the development of ...

On January 27, the company announced improvements to its RADR® AI platform aimed at accelerating and optimizing the development of antibody-drug conjugates (ADCs). ADC is a process of creating ...